Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | Lessons in lymphoma: highlights in the field of NHL

John Leonard • 17 Jan 2019
ASH 2018
Lymphoma Non-Hodgkin Lymphoma CAR-T Lenalidomide Rituximab
AUGMENT

John Leonard, MD, from Weill Cornell Medical College, New York City, NY, gives his insight into the key highlights from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, regarding non-Hodgkin lymphoma. Prof. Leonard discusses the clinical trials looking to maximize efficacy whilst reducing toxicity, offering an improved treatment landscape for patients.

More from John Leonard

Oral azacitidine plus R-CHOP for previously untreated NHL 1:53
Oral azacitidine plus R-CHOP for previously untreated NHL
John Leonard • 17 Jan 2019
AUGMENT-ing treatment: lenalidomide plus rituximab for R/R indolent NHL 2:05
AUGMENT-ing treatment: lenalidomide plus rituximab for R/R indolent NHL
John Leonard • 17 Jan 2019

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals